Another Heart Drug Fails, Shocking Cardiologists
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Another Heart Drug Fails, Shocking Cardiologists" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Bloomberg.com, statnews.com, Reuters and Novartis. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 71d ago.
Quick answers
Why is "Another Heart Drug Fails, Shocking Cardiologists" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (10)
- NVS, IONS, AMGN Stocks Drop After-Hours Yahoo Finance · 71d ago
- Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Business Wire · 71d ago
- Novartis announces Lp(a)HORIZON Phase III topline results GlobeNewswire · 71d ago
- Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal WSJ · 71d ago
- Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint WSJ · 71d ago
- Novartis Drug Fails Key Test for New Heart Disease Approach Bloomberg.com · 71d ago
- Novartis’ experimental cardiovascular drug fails a pivotal study statnews.com · 71d ago
- Ionis, Novartis' key experimental heart drug fails in late-stage trial Reuters · 71d ago
- Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Novartis · 71d ago
- Another Heart Drug Fails, Shocking Cardiologists nytimes.com · 71d ago
Topics
Related trends
Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial
The ZEUS clinical trial found that the anti-inflammatory drug ziltivekimab did not reduce major cardiovascular events in high-risk patients.
What Happens to Your Heart When You Take Creatine
Recent coverage examines the physiological effects of creatine on the heart, brain, and aging bodies across multiple outlets.
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
The US Food and Drug Administration and Health Canada have approved bepirovirsen, marketed as Hibsago, as the first functional cure for chronic hepatitis B.
Giardi: Another challenge for Maye on Sunday, but of late, he's been up for all of them
Sunday's Patriots‑Packers showdown pits Drake Maye against a revved‑up Packers defense in a high‑stakes quarterback duel.
Another 49ers receiver added to injury report ahead of Week 9 vs. Raiders
Injury reports dominate coverage as the 49ers and Raiders head toward their Week 9 matchup.
Another week, another BYU officiating controversy: 'Officials just making up rules'
Big 12 officials face intense scrutiny after admitting a replay review incorrectly awarded BYU a touchdown against Arizona State.